Skip to main content


Higher Rehospitalization Rates in Younger SLE Patients

Mar 08, 2023

A Medicare study shows that young adults with systemic lupus erythematosus (SLE) exhibit very high 30-day rehospitalization rates (36%) that are significantly higher than older SLE patients and age matched non-SLE patients.

This study was drawn from a 20% national Medicare sample from

Read Article

Does Biologic Treatment in Psoriasis Reduce the Risk of Psoriatic Arthritis?

Mar 07, 2023

Retrospective claims analysis shows that psoriasis patients treated with either an IL-12/23 inhibitor or an IL-23 inhibitor had a lower risk of developing incident psoriatic arthritis, compared to TNF inhibitors or IL-17 inhibitors.

There has been considerable debate whether

Read Article

Long-Term Benefit of Rituximab in Systemic Sclerosis

Mar 06, 2023

A small cohort trial of rituximab (RTX) in 29 systemic sclerosis patients showed significantly improved skin sclerosis and lung function after a follow-up of 96 weeks.

Read Article
Chest Pain & Fever Lessons from the clinic, brought to you by March 18 &19, 2023 - Dallas, TX
Specific ACPAs and Autoantibodies Lead to RA-Associated ILD

Specific ACPAs and Autoantibodies Lead to RA-Associated ILD

Feb 20, 2023

A BRASS registry study shows that specific isotypes of anti-citrullinated protein antibodies (ACPAs) can be associated with incident rheumatoid arthritis-associated ILD (RA-ILD). Early idtentification of RA-ILD is extremely important as it is a major contributor to premature death among

Read Article
Dr. Shenoi discusses a new bio markers in sJIA lung disease. #RWCS23 ⁦@RheumNow⁩ ⁦@RWCSmtg⁩
Subanalysis of Scleroderma Lung Study II (MMP vs CTX in SSc-ILD) showed pt reported GI reflux (~moderate) was independently associated with the change ILD and fibrosis over two years (but not so for esophageal dilation)
Elevated Uric Acid Is Associated With New‐Onset Atrial Fibrillation A Longitudinal Swedish study has shown that elevated serum uric acid (SUA) levels has cardiovascular implications and may predict the development of atrial fibrillation (AFib).

Poorer health outcomes for at-risk patients with fractures

Jan 18, 2023

People at high risk of fracture who also have complex or multiple chronic medical conditions are less likely to receive treatment for the underlying osteoporosis and also have poorer health outcomes, according to a new study from the Garvan Institute of Medical Research.  


Read Article

Elevated Uric Acid Is Associated With New‐Onset Atrial Fibrillation

Jan 16, 2023

A Longitudinal Swedish study has shown that elevated serum uric acid (SUA) levels has cardiovascular implications and may predict the development of atrial fibrillation (AFib). 

Read Article

Best of 2022: Approach to ILD in Myositis Syndromes

Dec 19, 2022

Mehta et al have published a full read review of managing interstitial lung disease (ILD) in patients with inflammatory myopathies, a heterogeneous group of syndromes connected by ILD and and increased morbidity and mortality risk.

Read Article

JAK Inhibitor Potential in Systemic Sclerosis-Associated ILD

Dec 15, 2022

The occurrence of interstitial lung disease (ILD) in Systemic sclerosis portends serious morbid and mortal outcomes for those affected. This review examines the available clinical literature on the potential benefits and outcomes of JAK inhibitor use in SSc=ILD.

Overall the authors

Read Article


Dec 01, 2022

A UK study suggests the equivalent outcomes when patients with interstitial lung disease (ILD) associated with connective tissue disease (CTD) are treated with either intravenous rituximab (RTX) or cyclophosphamide (CTX), but with fewer adverse events with RTX. 

Read Article

RA-ILD takes centre stage

Interstitial lung disease is common in RA, occurring in approximately 8% of RA patients. It is associated with a poor prognosis, and a median survival of 3 years. This important condition has often been neglected within the spectrum of RA research. That is changing, with excellent research

Read Article
Meng et al. ESR/CRP and steroid associated increased risk of MACE in IA. NSAIDs/COX-2 and MTX associated reduced risk of MACE in IA. @RheumNow #ACR22 Abstr#1207
Ab1486 #ACR22 @Keith_Colaco: Disease-specific CV Risk Prediction Model for PsO, PsA Prediction base model w only traditional CV risks excellent (AUC 85.5) Expanded model w damaged jts did not improve risk discrimination @Rheumnow
Multiplex peripheral blood in 200+ ILD pts Differences in IL-17 RD-ILD>IPF> IPAF Higher IL-13 strongly asso w/ non-progression of ILD in RD-ILD, IPF & IPAF OR 0.4 Almost surprising considering known profibrotic role of IL-13 🧐 Abs#1109 #ACR22 @Rheumnow
Early TNFi use and cardiovascular events in AS Abstract #0415 #ACR22 @RheumNow 📍17.6k patients, 91% male, 80% white 📍TNFi initiators were younger with lower prev. of HTN and DM 📍TNFi was associated with higher risk of incident CVD, CVA, and MACE
Broder et al. HCQ alone vs steroid alone as maintenance in ESKD due to SLE. HCQ less cardiac events, less infection. @RheumNow #ACR22 Abstr#0539
🧨Late breaking abstract🧨 #ACR22 @RheumNow #ACRbest Identifying fetal myocardial targets in congenital heart block (CHB) Abstract #L13 🫀maternal serum underwent mass spec. that identified Ab to 4 protein targets that predicted CHB including anti-ATP1A1 as early as 7w

RA-ILD: an update

Interstitial lung disease (ILD) remains a leading cause of mortality in rheumatoid arthritis (RA). Estimates of involvement of ILD in RA remain relatively imprecise (estimated prevalence 5-20%), though this partly reflects the wide spectrum of ILD and differing ascertainment.

Read Article
Among ANCA-vasculitis hospitalizations, A Fib found to be most common CV condition. Females had fewer CV complications, lower in-hospital mortality & shorter length of stay compared to males. Abs 0434 #ACR22

ACR Best Abstracts - Day 1

Nov 12, 2022

The RheumNow faculty reporters have been scouring the meeting and online presentations to find the best abstracts from ACR22. Here are some of their choice abstracts reported today on day 1 of ACR 2022 (#ACRbest).


Read Article
Liew @rheum_cat et al. No evidence of cardioprotective effect of early initiation of TNFi in AxSpA. In fact seemed to be associated higher risk! CVD (HR 1.17), stroke (HR 1.24), and MACE (HR 1.22) @rheumnow #ACR22 Abstr#0415